TCCSUPHomo sapiens (Human)Cancer cell line
Also known as: TCC Sup, TCC-SUP, TCCSuP, JCCSUP
Quick Overview
Human bladder cancer cell line with known mutations and drug resistance profiles.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1738 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Urinary bladder[UBERON:UBERON_0001255] |
Donor Information
| Age | 67 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Bladder carcinoma |
|---|---|
| Lineage | Bladder/Urinary Tract |
| Subtype | Bladder Urothelial Carcinoma |
| OncoTree Code | BLCA |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000720_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Glu349Ter (c.1045G>T) | Unspecified | - | PubMed=16203773 |
| MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Bladder Cancer 4:169-183(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.
Oncogene 36:35-46(2017).
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Transl. Oncol. 8:210-216(2015).
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Chanock S.J., Valencia A., Real F.X.
BMC Genomics 16:403.1-403.16(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Knowles M.A.
PLoS ONE 8:E84411-E84411(2013).
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Hurst C.D., Platt F.M., Knowles M.A.
Eur. Urol. 65:367-369(2014).
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.
Eur. Urol. 65:360-366(2014).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Immunocytochemical analysis of cell lines derived from solid tumors.
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
J. Histochem. Cytochem. 49:1369-1378(2001).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Markl I.D.C., Jones P.A.
Cancer Res. 58:5348-5353(1998).
p53 mutations in bladder carcinoma cell lines.";
Lippa M., Hatzivassiliou G., Tan J.
Oncol. Res. 6:569-579(1994).
Lectins as probes for identification of tumor-associated antigens on urothelial and colonic carcinoma cell lines.
Paulie S., Hansson Y., Lundblad M.-L., Perlmann P.
Int. J. Cancer 31:297-303(1983).
Identity of some human bladder cancer cell lines.";
O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.
Nature 301:429-430(1983).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
Polymorphic enzyme analysis of cultured human tumor cell lines.";
Dracopoli N.C., Fogh J.
J. Natl. Cancer Inst. 70:469-476(1983).
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Franks L.M.
Cancer Res. 46:3630-3636(1986).
A cell line from an anaplastic transitional cell carcinoma of human urinary bladder.
Nayak S.K., O'Toole C.M., Price Z.H.
Br. J. Cancer 35:142-151(1977).
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Fogh J.
Natl. Cancer Inst. Monogr. 49:5-9(1978).